eBook - ePub
Medical Physics
Models and Technologies in Cancer Research
Anna Bajek, Bartosz Tylkowski, Anna Bajek, Bartosz Tylkowski
This is a test
- 263 pages
- English
- ePUB (adapté aux mobiles)
- Disponible sur iOS et Android
eBook - ePub
Medical Physics
Models and Technologies in Cancer Research
Anna Bajek, Bartosz Tylkowski, Anna Bajek, Bartosz Tylkowski
DĂ©tails du livre
Aperçu du livre
Table des matiĂšres
Citations
Ă propos de ce livre
Modern cancer research is a high-tech undertaking, overlapping with many fields in the physical sciences. These include nanotechnology, engineering, immunology, and bioinformatics. This book focuses on the science and technology underlying the diagnosis and treatement of cancer. The authors offer insights into technologies including radiotherapy, modelling, and drug encapsulation.
Foire aux questions
Comment puis-je résilier mon abonnement ?
Il vous suffit de vous rendre dans la section compte dans paramĂštres et de cliquer sur « RĂ©silier lâabonnement ». Câest aussi simple que cela ! Une fois que vous aurez rĂ©siliĂ© votre abonnement, il restera actif pour le reste de la pĂ©riode pour laquelle vous avez payĂ©. DĂ©couvrez-en plus ici.
Puis-je / comment puis-je télécharger des livres ?
Pour le moment, tous nos livres en format ePub adaptĂ©s aux mobiles peuvent ĂȘtre tĂ©lĂ©chargĂ©s via lâapplication. La plupart de nos PDF sont Ă©galement disponibles en tĂ©lĂ©chargement et les autres seront tĂ©lĂ©chargeables trĂšs prochainement. DĂ©couvrez-en plus ici.
Quelle est la différence entre les formules tarifaires ?
Les deux abonnements vous donnent un accĂšs complet Ă la bibliothĂšque et Ă toutes les fonctionnalitĂ©s de Perlego. Les seules diffĂ©rences sont les tarifs ainsi que la pĂ©riode dâabonnement : avec lâabonnement annuel, vous Ă©conomiserez environ 30 % par rapport Ă 12 mois dâabonnement mensuel.
Quâest-ce que Perlego ?
Nous sommes un service dâabonnement Ă des ouvrages universitaires en ligne, oĂč vous pouvez accĂ©der Ă toute une bibliothĂšque pour un prix infĂ©rieur Ă celui dâun seul livre par mois. Avec plus dâun million de livres sur plus de 1 000 sujets, nous avons ce quâil vous faut ! DĂ©couvrez-en plus ici.
Prenez-vous en charge la synthÚse vocale ?
Recherchez le symbole Ăcouter sur votre prochain livre pour voir si vous pouvez lâĂ©couter. Lâoutil Ăcouter lit le texte Ă haute voix pour vous, en surlignant le passage qui est en cours de lecture. Vous pouvez le mettre sur pause, lâaccĂ©lĂ©rer ou le ralentir. DĂ©couvrez-en plus ici.
Est-ce que Medical Physics est un PDF/ePUB en ligne ?
Oui, vous pouvez accĂ©der Ă Medical Physics par Anna Bajek, Bartosz Tylkowski, Anna Bajek, Bartosz Tylkowski en format PDF et/ou ePUB ainsi quâĂ dâautres livres populaires dans Physical Sciences et Physics. Nous disposons de plus dâun million dâouvrages Ă dĂ©couvrir dans notre catalogue.
Informations
1 Personalized and targeted therapies
Magdalena WiĆniewska
Department of Oncology and Brachytherapy, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, ToruĆ, Poland
Department of Clinical Oncology, Oncology Centre, Bydgoszcz, Poland
MichaĆ WiĆniewski
Outpatient Chemotherapy Department, Oncology Centre, Bydgoszcz, Poland
Marzena A. Lewandowska
Department of Thoracic Surgery and Tumors, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, ToruĆ, Poland
Oncology Centre, Bydgoszcz, Poland
Department of Molecular Oncology and Genetics, Innovative Medical Forum Oncology Centre, Bydgoszcz, Poland
ORCID:https://orcid.org/0000-0002-7360-7810
Ludwik Rydygier Collegium Medicum Nicolaus Copernicus University (UMK CM 2018 WL 103 and UMK CM 2020 WL 183)
This article has previously been published in the journal Physical Sciences Reviews. Please cite as: WiĆniewska, M., WiĆniewski, M., Lewandowska, M. A. Personalized and targeted therapies Physical Sciences Reviews [Online] 2021, 6 DOI: 10.1515/psr-2019-0057
Abstract
Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure. There are several categories of biomarkers but predictive biomarkers play the most important role in the treatment of neoplasms. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Identification of predictive biomarkers allows the development of novel targeted therapies resulting in tailored treatment. In this chapter we discuss most important predictive biomarkers used in contemporary oncology for which there is approved therapies.
Keywords: biomarker, predictive biomarkers, tailored treatment, targeted therapies,
1.1 Introduction
Biomarkers are critical to the rational development of medical diagnostics and therapeutics [1]. Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure, according to Food and Drug Administration â National Institute of Health (FDA-NIH) Working Group [2].
There are several categories of biomarkers according to FDA-NIH classification. Predictive biomarkers can be used to identify response to exposure to a therapy or an environmental agent. The response could be a relief of symptoms, improvement in survival, or an adverse effect [2]. Predictive biomarkers are essential to modern personalized therapy in contemporary oncology and are the topic of this chapter. Other categories of biomarkers according to FDA-NIH classification include diagnostic, prognostic, monitoring, safety and pharmacodynamic biomarkers.
1.1.1 Predictive biomarkers
Predictive biomarkers are the most important in the treatment of neoplastic diseases. Their presence allows predicting in which group of patients the therapy will be effective. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Table 1.1 represents the broad range of biomarkers, which are analyzed in nonâsmall cell lung cancer to qualify patient for appropriate therapy. There are also biomarkers whose presence is associated with the effectiveness of a given therapy regardless of the type of tumor (so-called organ-independent biomarkers), examples of such biomarkers are mutations in the NTRK or high levels of MSI. In this chapter, predictive biomarkers for which there are approved therapies in the treatment of solid tumors will be discussed.
Disease | Biomarker | Drug |
---|---|---|
Non-small cell lung cancer | EGFR | Erlotinib |
Gefitinib | ||
Osimertinib | ||
Afatinib | ||
Dacomotinib | ||
ALK | Crizotinib | |
Ceritinib | ||
Lorlatinib | ||
Alectinib | ||
Brigantinib | ||
ROS1 | Crizotinib | |
Ceritinib | ||
Lorlatinib | ||
Alectinib | ||
Brigantinib | ||
BRAF | Dabrafenib | |
Vumurafenib | ||
MEK | Capmatinib | |
RET | Selpercatinib | |
PD-L1 | Pembrolizumab | |
NTRK | Entrectinib | |
Larotrektinib | ||
No biomarker | Chemotherapy |
1.1.2 Diagnostic biomarker
Diagnostic biomarker is used as an indicator of a presence of a disease or condition to assess a subtype of the disease, e.g. profiling of gene expression may be used to distinguish subgroups of patients with diffuse large B-cell lymphoma and different gene signatures of malignant cells. Another example of diagnostic biomarker could be measurement of glomerular filtration rate [GFR] in diagnosis of patients with chronic kidney disease [3, 4].
1.1.3 Monitoring biomarker
Monitoring biomarker is an indicator of disease or medical condition status. It may also indicate an effect of a drug of environmental factor. Examples of monitoring biomarkers are prostate-specific antigen (PSA) in patients with prostate cancer or cancer antigen 125 (CA 125) in patients with ovarian cancer. Both biomarkers are used to assess disease status or burden [5, 6].
1.1.4 Risk (screening) biomarkers
Risk (screening) biomarkers indicate the potential for developing a disease or medical condition in an individual who does not currently have clinically apparent disease or the medical condition. Example of risk biomarkers are mutations in genes related to increased risk of developing cancer as BRCA 1/2 (Breast Cancer genes 1 and 2) mutations which are inked with breast cancer [7, 8].
1.1.5 Pharmacodynamic (response) biomarkers
Pharmacodynamic (response) biomarkers indicate a biological response that may be seen in a patient treated with a drug or an environmental factor. Example of a such biomarker is a standardized uptake value (SUV) measured by PET/CT (Positon Emission Tomography/Computed Tomography) with 18-FG-glucose marked contrast, used as a response biomarker when assessing a response in a patients treated with chemotherapy for diffuse large B-cell lymphoma or Hodgkin lymphoma [9, 10].
1.1.6 Safety biomarker
Safety biomarker is measured for determining a risk of toxicity or an adverse effect. It may be assessed after or before an exposure to a drug or an environmental factor. Safety biomarker example cloud be a serum creatinine for monitoring renal toxicity in a patients treated with a potentially...
Table des matiĂšres
- Title Page
- Copyright
- Contents
- List of contributing authors
- 1âPersonalized and targeted therapies
- 2âAdvancements in cancer chemotherapy
- 3âPrinciples of radiation therapy
- 4âAdvanced cell culture techniques for cancer research
- 5âNatural substances in cancerâdo they work?
- 6âThe application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer
- 7âNon-radioactive imaging strategies for in vivo immune cell tracking
- 8âPresent trends in the encapsulation of anticancer drugs
- 9â3D tumor model â a platform for anticancer drug development
- Index
Normes de citation pour Medical Physics
APA 6 Citation
[author missing]. (2021). Medical Physics (1st ed.). De Gruyter. Retrieved from https://www.perlego.com/book/2818454/medical-physics-models-and-technologies-in-cancer-research-pdf (Original work published 2021)
Chicago Citation
[author missing]. (2021) 2021. Medical Physics. 1st ed. De Gruyter. https://www.perlego.com/book/2818454/medical-physics-models-and-technologies-in-cancer-research-pdf.
Harvard Citation
[author missing] (2021) Medical Physics. 1st edn. De Gruyter. Available at: https://www.perlego.com/book/2818454/medical-physics-models-and-technologies-in-cancer-research-pdf (Accessed: 15 October 2022).
MLA 7 Citation
[author missing]. Medical Physics. 1st ed. De Gruyter, 2021. Web. 15 Oct. 2022.